Compare RNW & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | HRMY |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United Kingdom | United States |
| Employees | 4336 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | RNW | HRMY |
|---|---|---|
| Price | $4.83 | $29.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 823.4K | 605.9K |
| Earning Date | 02-16-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $11.50 | $12.88 |
| P/E Ratio | $14.63 | ★ $10.72 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $4.39 | $25.52 |
| 52 Week High | $8.24 | $40.87 |
| Indicator | RNW | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 56.76 |
| Support Level | $4.39 | $25.92 |
| Resistance Level | $5.58 | $30.96 |
| Average True Range (ATR) | 0.14 | 0.82 |
| MACD | 0.03 | 0.42 |
| Stochastic Oscillator | 71.03 | 91.72 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.